Skip to search formSkip to main contentSkip to account menu

Atu027

Known as: Anti-PKN3 siRNA Atu027 
A lipoplexed formulation consisting of short-interfering RNAs (siRNAs) directed against protein kinase N3 (PKN3) encapsulated in catiogenic and… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Ten years after Fire and Melo’s Nobel Prize for discovery of gene silencing by double-stranded RNA, a remarkable progress was… 
2016
2016
385 Background: Atu027 is a liposomally formulated short interfering RNA with anti-metastatic activity, which silences expression… 
Highly Cited
2014
Highly Cited
2014
PURPOSE Atu027 is a novel liposomal RNA interference therapeutic that includes a short-interfering RNA (siRNA), which silences… 
2014
2014
siRNA clinical trials: state of the art With the emergence of siRNA-based nanomedicine as a powerful therapeutic strategy for… 
2013
2013
2508 Background: Atu027 is a novel vascular stabilising, anti-metastatic, RNAi therapeutic, targeting systemic endothelial cell… 
Highly Cited
2012
Highly Cited
2012
Chemically synthesized, small interfering RNAs (siRNA) are currently used as a new class of therapeutic molecules, allowing the… 
2012
2012
e13597 Background: Atu027 contains siRNA-lipoplexes, which elicits RNAi mediated suppression on PKN3 in vascular endothelial… 
2011
2011
3057 Background: Atu027 is a novel RNAi therapeutic based on cationic lipoplexes containing chemically stabilized siRNAs, which… 
Highly Cited
2010
Highly Cited
2010
Purpose: Atu027, a novel RNA interference therapeutic, has been shown to inhibit lymph node metastasis in orthotopic prostate… 
Highly Cited
2008
Highly Cited
2008
We have previously described a small interfering RNA (siRNA) delivery system (AtuPLEX) for RNA interference (RNAi) in the…